Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.39 |
| ▸ | HRH2 | P25021 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | DRD5 | P21918 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17192147 | 1.00 | GID4 (0.42) | GID4HRH3HRH2HTR2CDRD2 | |
| SCHEMBL12270073 | 1.00 | GID4 (0.42) | GID4HRH3HRH2HTR2CDRD2 | |
| SCHEMBL17969853 | 0.89 | GID4 (0.45) | GID4HTR2CDRD2DRD1DRD4 | |
| SCHEMBL29659736 | 0.81 | ADRA2A (0.44) | HRH3HRH2HTR2CALDH1A1 | |
| SCHEMBL598145 | 0.81 | ADRA2A (0.44) | HRH3HRH2HTR2CALDH1A1 | |
| SCHEMBL23854048 | 0.79 | GID4 (0.44) | GID4DRD2DRD1DRD4DRD5 | |
| SCHEMBL12434036 | 0.79 | HRH3 (0.35) | HRH3HRH2HTR2CALDH1A1 | |
| SCHEMBL12434029 | 0.79 | HRH3 (0.35) | HRH3HRH2HTR2CALDH1A1 | |
| SCHEMBL13616719 | 0.78 | KMT2A (0.44) | GID4DRD2DRD1DRD4DRD5 | |
| SCHEMBL13974016 | 0.78 | KMT2A (0.44) | GID4DRD2DRD1DRD4DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9481659-B2 | Selective heterocyclic sphingosine 1 phosphate receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2016-11-01 | — | — | US | disclosed |
| US-20150299179-A1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | RECEPTOS, INC. (US) | 2015-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299179-A1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | S1PR1, S1PR3, S1PR2 | GID4 1514/4885HRH3 328/4885HRH2 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.